As the Director of Medical Writing at Regeneron, Susan Gillette leverages her extensive 16 years of experience in pharmaceutical drug development and 13 years in government and academic research to lead a dynamic team of medical writers. Her role encompasses the supervision of both internal...
As the Director of Medical Writing at Regeneron, Susan Gillette leverages her extensive 16 years of experience in pharmaceutical drug development and 13 years in government and academic research to lead a dynamic team of medical writers. Her role encompasses the supervision of both internal and external writers, ensuring the preparation of high-quality scientific and clinical documents that meet regulatory standards and effectively communicate complex scientific concepts. Susan's expertise in scientific writing is complemented by her deep understanding of Good Laboratory Practices (GLP), animal models, and the intricacies of inflammation and neurodegeneration research, which are critical in the development of innovative therapies.
In her position, Susan not only oversees the writing function but also plays a pivotal role in fostering a collaborative and inclusive team environment. She promotes effective communication among her team members, guiding them through challenges and facilitating the resolution of issues that may arise during the writing process. Her leadership extends beyond project management; she actively participates in strategic discussions with upper management to shape the direction of the writing function, ensuring alignment with Regeneron’s broader objectives.
Susan is passionate about diversity and inclusion within the workplace, recognizing that a diverse team enhances creativity and problem-solving capabilities. By investing in leadership development and encouraging open dialogue, she cultivates a culture where all voices are heard, ultimately driving the success of key projects. Her commitment to clear and accurate communication not only elevates the quality of scientific documentation but also strengthens Regeneron’s reputation as a leader in biopharmaceutical innovation.
